Phage Display Reveals VLRB-Mediated Recognition of Minimal Tumor Glycan Antigen Sialyl-Tn

Mark Rickard N Angelia1,2, Abigail Joy D Rodelas-Angelia1, Youngrim Kim1

  • 1Laboratory of Aquatic Animal Diseases, Institute of Animal Medicine, College of Veterinary Medicine, Gyeongsang National University, 501, Jinju-Daero, Jinju-si 52828, Republic of Korea.

PubMed

Insights

Variable lymphocyte receptor B (VLRB) ccombodies were developed to detect Sialyl-Tn (sTn), a tumor antigen. These VLRBs show high affinity and specificity for sTn, offering a new tool for cancer diagnostics and therapeutics.

Area of Science:

  • Biochemistry
  • Immunology
  • Glycobiology

Background:

  • Sialyl-Tn (sTn) is a tumor-associated carbohydrate antigen (TACA) found in many carcinomas.
  • Conventional antibody platforms for sTn detection have limitations.
  • Variable lymphocyte receptor B (VLRB) from jawless vertebrates presents an alternative scaffold for glycan recognition.

Purpose of the Study:

  • To identify and characterize novel sTn-specific binding molecules using VLRBs.
  • To evaluate VLRB-based binders as alternatives to antibodies for targeting tumor-associated glycans.

Main Methods:

  • Construction and screening of a phage-displayed VLRB library against sTn.
  • Isolation and purification of VLRB candidates (ccombodies A8 and B11).
  • Biochemical characterization using SDS-PAGE, ELISA, and inhibition assays with Vicia villosa lectin.

Main Results:

  • Two high-affinity VLRB binders, A8 and B11, were identified with nanomolar EC50 values for sTn.
  • VLRB binders demonstrated specificity for sTn and other core α-GalNAc-containing O-glycans.
  • ccombodies bound to sTn-positive glycoproteins and carcinoma cell lines (HeLa, LS174T).

Conclusions:

  • Phage display of VLRBs is effective for generating high-affinity, glycan-specific binders.
  • VLRB-based ccombodies offer a promising alternative to antibodies for targeting tumor-associated glycans.
  • These findings support the development of VLRB scaffolds for cancer diagnostics and therapeutics.